OncoMatch/Clinical Trials/NCT07023484
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Is NCT07023484 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Carboplatin plus Paclitaxel for ovarian cancer.
Treatment: Carboplatin plus Paclitaxel — About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 any tested
Required: BRCA2 any tested
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
adequate hematologic function for chemotherapy
Kidney function
adequate renal function for chemotherapy
Liver function
adequate liver function for chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07023484 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require BRCA1?
Yes, BRCA1 any tested is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages